Podcast CE: Panoquell-CA1 and its role in the management of acute pancreatitis

Sponsored by Ceva Animal Health, LLC. Head to dvm360 Flex and login or create a free CE account and claim your credit after listening to this episode.

In this podcast Dr. Harry Cridge, an ACVIM and ECVIM board-certified specialist in small animal internal medicine, will discuss his approach to the management of pancreatitis in dogs. This podcast will include discussion of Panoquell®-CA1, a novel and innovative solution for neutrophilic inflammation in acute pancreatitis.

Program agenda:

Management of acute pancreatitis

• Supportive care – intravenous fluids, nutrition, anti-nausea medications, and analgesia
• Targeted therapies – Panoquell®-CA1

Learning objectives:

• Recall the mechanism of action of Panoquell®-CA1.
• Identify potential adverse effects for drugs in the management of pancreatitis.
• Develop a treatment plan for a dog with suspected pancreatitis.

PANOQUELL®-CA1 (fuzapladib sodium for injection)

PANOQUELL® is a registered trademark of Ishihara Sangyo Kaisha, Ltd.

© 2023 Ceva Animal Health, LLC

PANOQUELL®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141 to 567. It is a violation of federal law to use this product other than as directed in the labeling. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

*IMPORTANT SAFETY INFORMATION: The safe use of PANOQUELL®-CA1 has not been evaluated in dogs with cardiac disease, hepatic failure, or renal impairment; dogs that are pregnant, lactating, or intended for breeding; or puppies under 6 months of age. PANOQUELL®-CA1 should not be used in dogs with a known hypersensitivity to fuzapladib sodium. PANOQUELL®-CA1 is a highly protein-bound drug and its use with other highly protein-bound medications has not been studied. The most common adverse effects in the pilot field study were anorexia, digestive tract disorders, respiratory tract disorders, and jaundice. PANOQUELL®-CA1 is not for use in humans. Limited data is available on the potential teratogenic effects of fuzapladib sodium. Therefore, anyone who is pregnant, breastfeeding, or planning to become pregnant should avoid direct contact with PANOQUELL®-CA1. For additional information on the use of PANOQUELL®-CA1, please refer to the package insert.

See prescribing and product information: https://www.panoquell.com/